Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY 3630942 Imaging in HCC and Solid Tumors
NCT06345001Phase 1Completed
- Sponsor
- Bayer
- Start
- Aug 2024
- Primary completion
- Mar 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of BAY3630942 in hepatocellular carcinoma (HCC) and solid tumor (2 arms), sponsored by Bayer. Primary endpoints: Radioactivity concentration of BAY 3630942 in normal organs up to 12 days, Zirconium-89 absorbed doses in normal organs up to 12 days and 1 more. Started Aug 2024; status: completed.
02
Drugs
BAY3630942
03
Conditions
hepatocellular carcinoma (HCC)solid tumor
Beyond the preview
Go deeper on NCT06345001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06345001.